Literature DB >> 1927890

Glomerular capillary pressure and hypertension.

P Larochelle1.   

Abstract

In patients with essential hypertension, glomerular filtration rate remains normal or elevated, whereas renal blood flow tends to be lower, which results in an increased filtration fraction. The afferent (preglomerular) arteriolar resistance determines the fraction of the pressure that is transmitted to the glomerular capillary network, whereas the efferent (postglomerular) arteriolar resistance determines the outgoing pressure. The relationship between these two resistances, renal plasma flow and the ultrafiltration coefficient will determine the glomerular capillary pressure. In hypertension the glomerular capillary pressure tends to increase because the reduction in afferent arteriolar resistance is greater than the reduction in efferent resistance. Because these resistances and the systemic pressure do not change similarly, reduction in systemic pressure may not translate necessarily or completely into a reduction of glomerular capillary pressure. The choice of antihypertensive drugs may influence the progression of any reduction in renal function based as much on their effect on the glomerular capillary pressure as on their effect on the systemic pressure.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1927890     DOI: 10.1016/0002-8703(91)90945-e

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  2 in total

1.  Questioning the renoprotective role of L-type calcium channel blockers in chronic kidney disease using physiological modeling.

Authors:  Kyle H Moore; John S Clemmer
Journal:  Am J Physiol Renal Physiol       Date:  2021-09-06

2.  Estimation of the relationship between the polymorphisms of selected genes: ACE, AGTR1, TGFβ1 and GNB3 with the occurrence of primary vesicoureteral reflux.

Authors:  Marcin Życzkowski; Joanna Żywiec; Krzysztof Nowakowski; Andrzej Paradysz; Władyslaw Grzeszczak; Janusz Gumprecht
Journal:  Int Urol Nephrol       Date:  2016-12-17       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.